Cell Therapeutics, Inc. to Hold Conference Call to Update on Recent Transactions and Upcoming ...( SEATTLE March 4 /- On Wednesday M...)
Navigation Links
| HOME >> BIOLOGY >> TECHNOLOGY |
Cell Therapeutics, Inc. to Hold Conference Call to Update on Recent Transactions and Upcoming Milestones
Date:3/4/2008
SEATTLE, March 4 /PRNewswire-FirstCall/ -- On Wednesday, March 5, 2008,
at 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific Time
members of Cell Therapeutics, Inc.'s (CTI) (Nasdaq: CTIC and MTAX: CTIC)
management team will host a conference call to discuss the company's recent
transactions targeting cleaning up the capital structure, and upcoming
product and sales milestones.
Conference Call Numbers
Wednesday, March 5
8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific Time
1-800-257-7063 (US Participants)
1-303-262-2139 (International)
Live audio webcast at
will be archived for post listening
approximately two hours after call ends
Call-back numbers for post-listening available at 10:30 AM ET:
1-800-405-2236 (US Participants)
1-303-590-3000 (International)
Passcode: 11110227#
Media Contact:
Cell Therapeutics, Inc.
Dan Eramian
T: 206.272.4343
C: 206.854.1200
F: 206.272.4434
http://www.cticseattle.com/media.htm
Investors Contact:
Cell Therapeutics, Inc.
Leah Grant
T: 206.282.7100
F: 206.272.4434
| SOURCE Cell Therapeutics, Inc. Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. M. Scott Harris, M.D., Joins Ocera Therapeutics, Inc., as Chief Medical Officer
2. Cell Therapeutics, Inc. (CTI) Announces Cancellation of Approximately $9.1 Million of Existing Notes due 2008
3. Mersana Therapeutics, Inc. Appoints Chief Scientific Officer, Timothy B. Lowinger, Ph.D.
4. Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008
5. Cell Therapeutics, Inc. (CTI) to Present at 10th Annual BIO CEO & Investor Conference
6. Nile Therapeutics, Inc. to Present at Upcoming BIO CEO & Investor Conference
7. Velcura Therapeutics, Inc. Teams with International Discovery Sourcing Consultants to Develop New Therapeutic Molecules for Cancer and Bone Disease
8. Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimers Treatments
9. Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc.
10. Cell Therapeutics, Inc. (CTI) Shareholders Authorize Share Increase at Special Meeting of Shareholders
11. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
Post Your Comments:
(Date:11/20/2009)...ntly announced that Dr. Dominique Hebrault will pr...nalytical Technology (PAT) in Green Chemistry and ... (PRWEB) November 20, 2009 -...ology (PAT) in Green Chemistry and Green Engineeri...nology (PAT) case studies will be presented on how...
(Date:11/19/2009)...e/ -- Dr. Mate Hidvegi, inventor of Avemar ferment... issued on November 17 by Biropharma Kft, discredi...lf-serving statements about its U.S. competitor Am... his office in Budapest, Hungary: ,, "The Biro...y to AveULTRA, www.aveultra.com , is misleading...
(Date:11/19/2009)...., Nov. 19 Arlington Medical Resou...ading driver of antibiotic selection in nosocomial...ainst gram-positive and gram-negative pathogens. D...comial pneumonia, surveyed European physicians rev...de appropriate coverage against common pathogens, ...
(Date:11/19/2009)...nthesis Companies Form International Gene Synthesi...n Risk Reduction ,Five Member Companies Represen... , (PRWEB) November 19, 20...esis companies today announced agreement that they... biosecurity in the gene synthesis industry. By s...
Breaking Biology Technology:Process Analytical Technology (PAT) in Green Chemistry and Green Engineering 2American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 3World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 4[0] Process Analytical Technology (PAT) in Green Chemistry and Green Engineering[0] American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor[0] Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe[0] World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol
...ate vaccines for avian flu through genet...CKVILLE, Md., Nov. 13 Novavax, Inc.,(Nasdaq: NVA... avian flu,through genetically-engineered virus-li...tion at Cleveland Clinic 6th Annual Medical Innova...initiatives have the potential to,impact millions ...
... Genaera,Corporation (Nasdaq: GENR ) will presen...the Congress Center in Mannheim, Germany. Dr. Henr...ific Officer, will present,a company overview on T...ut Genaera, Genaera Corporation is developing tro...ity currently in phase 1 clinical testing and has ...
...nta Holding,Corporation (NYSE: CVA ), a world lea...rgy-from-Waste and renewable energy facilities, to... purchase two biomass energy,facilities from co-ow...vices, Inc., Pursuant to the amended agreement, C...for approximately $52 million subject to working c...
Other Biology Technology:Cleveland Clinic Recognizes New Strategies for Creating Vaccines for Avian Flu as a Top Ten Medical Innovation for 2009 2Cleveland Clinic Recognizes New Strategies for Creating Vaccines for Avian Flu as a Top Ten Medical Innovation for 2009 3Cleveland Clinic Recognizes New Strategies for Creating Vaccines for Avian Flu as a Top Ten Medical Innovation for 2009 4Genaera to Present at BIO-Europe 2008 2Covanta Announces Amended Terms for its Acquisition of Two Biomass Energy Facilities in Maine 2Covanta Announces Amended Terms for its Acquisition of Two Biomass Energy Facilities in Maine 3Covanta Announces Amended Terms for its Acquisition of Two Biomass Energy Facilities in Maine 4(Date:11/23/2009)...e in German . , Not just birds, but also a .... Researchers at Princeton University in the U.S. ... Radolfzell, Germany studied the migratory behavio...lled "Vespertilionidae" with the help of mathemati...r short as well as long distances of various kinds...
(Date:11/22/2009)...cientists have inventoried an astonishing abundanc...that have never known sunlight - creatures that so... to 5,000 meters (~3 miles) below the ocean waves....ther vanguard technologies, animals known to thriv... a diverse collection of species ranging from crab...
(Date:11/22/2009)...esearch Centre, a partnership of the University of...r Coastal Health Research Institute, have uncovere...in cells die following a stroke, as well as a poss...he study were recently published online in Nature...ls continue to die even after blood flow has been ...
Breaking Biology News(10 mins):We're off then: The evolution of bat migration 2Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 2Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 3Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 4Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 5Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 6Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 7Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 8Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 9New understanding about mechanism for cell death after stroke leads to possible therapy 21 in 4 nursing home residents carry MRSA 47915 11 in 4 nursing home residents carry MRSA 47915 2New Option for Erasing Wrinkles 47913 1New Option for Erasing Wrinkles 47913 2New Option for Erasing Wrinkles 47913 3New Option for Erasing Wrinkles 47913 4Keys to a Fit Pregnancy and Losing the Baby Weight 47910 1Keys to a Fit Pregnancy and Losing the Baby Weight 47910 2Keys to a Fit Pregnancy and Losing the Baby Weight 47910 3...s discovered a new ultra-small species of bacteria...hin the ice of a Greenland glacier at a depth of n...ersist in this low-temperature, high-pressure, red...rticularly useful for studying how life, in genera...s on Earth and possibly elsewhere in the solar sys...
...m among scientists has long been that birds acquir...ood health from their environment, but a new Unive...ually born with those bacteria. , Lead author Adr... at the American Society for Microbiology General ...ns for the poultry industry and for food safety. ,...
... commonplace everyday events than meets the eye. T...m a tap, are two such events, both of which involv...cated mathematical techniques to describe, analyse...in common between many such singular events across...actions to the very formation of the universe itse...
Other Biology News:A survivor in Greenland: A novel bacterial species is found trapped in 120,000-year-old ice 2Study finds healthy intestinal bacteria within chicken eggs 2Finding out what the Big Bang and ink jets have in common 2Finding out what the Big Bang and ink jets have in common 3Direct ELISA Assay Diluent from BioFX Laboratories, Inc.
Direct ELISA Assay Diluent - EDTA from BioFX Laboratories, Inc.
Rabbit Anti-Mouse Junctophilin-4, C-Terminus Monoclonal Antibody, Unconjugated, Clone PADZMD.487 from Invitrogen
Fluorescence Preserving Media from BioFX Laboratories, Inc.
Biology Products:| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |